Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders.
Pharmacological and anatomical evidence suggests that abnormal glutamate neurotransmission may be associated with the pathophysiology of schizophrenia and mood disorders. Medial temporal lobe structural alterations have been implicated in schizophrenia and to a lesser extent in mood disorders. To comprehensively examine the ionotropic glutamate receptors in these illnesses, we used in situ hybridization to determine transcript expression of N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), and kainate receptor subunits in the medial temporal lobe of subjects with schizophrenia, bipolar disorder (BD), or major depression (MDD). We used receptor autoradiography to assess changes in glutamate receptor binding in the same subjects. Our results indicate that there are region- and disorder-specific abnormalities in the expression of ionotropic glutamate receptor subunits in schizophrenia and mood disorders. We did not find any changes in transcript expression in the hippocampus. In the entorhinal cortex, most changes in glutamate receptor expression were associated with BD, with decreased GluR2, GluR3, and GluR6 mRNA expression. In the perirhinal cortex we detected decreased expression of GluR5 in all three diagnoses, of GluR1, GluR3, NR2B in both BD and MDD, and decreased NR1 and NR2A in BD and MDD, respectively. Receptor binding showed NMDA receptor subsites particularly affected in the hippocampus, where MK801 binding was reduced in schizophrenia and BD, and MDL105,519 and CGP39653 binding were increased in BD and MDD, respectively. In the hippocampus AMPA and kainate binding were not changed. We found no changes in the entorhinal and perirhinal cortices. These data suggest that glutamate receptor expression is altered in the medial temporal lobe in schizophrenia and the mood disorders. We propose that disturbances in glutamate-mediated synaptic transmission in the medial temporal lobe are important factors in the pathophysiology of these severe psychiatric illnesses.
Beneyto
Monica
M
Department of Psychiatry, University of Pittsburgh, 3801 O'Hara Street, Pittsburgh, PA 15213, USA. beneytom@upmc.edu
Kristiansen
Lars V
LV
Oni-Orisan
Akinwunmi
A
McCullumsmith
Robert E
RE
Meador-Woodruff
James H
JH
D015763:2-Amino-5-phosphonovalerate / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D000328:Adult; D000704:Analysis of Variance; D001345:Autoradiography / Q000379:methods; D018691:Excitatory Amino Acid Antagonists / Q000493:pharmacokinetics; D005260:Female; D005786:Gene Expression Regulation / Q000502:physiology*; D006801:Humans; D017403:In Situ Hybridization / Q000379:methods; D007211:Indoles / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000378:metabolism / Q000473:pathology*; D011180:Postmortem Changes; D011485:Protein Binding / Q000187:drug effects / Q000502:physiology; D017470:Receptors, Glutamate / Q000145:classification / Q000235:genetics / Q000378:metabolism*; D012559:Schizophrenia / Q000378:metabolism / Q000473:pathology*; D013702:Temporal Lobe / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology
D018691:Excitatory Amino Acid Antagonists; D007211:Indoles; C101788:MDL 105519; D017470:Receptors, Glutamate; C069052:CGP 39653; D015763:2-Amino-5-phosphonovalerate